drugset

drugset / Trial / NCT05177640

Biodistribution and Dosimetry of 99mTc-Duramycin

NCT05177640 ↗

Phase 1 Completed 6 enrolled University Hospital, Antwerp Molecular Targeting Technologies, Inc. · collab

NaSingle-groupOpen-labelDiagnostic

Summary

Conduct a first-in-human study in healthy volunteers to show safety, biodistribution and dosimetry of \[99mTc\]Duramycin.

Timeline

Start: 2021-06-17
Primary completion: 2021-12-14
Completion: 2021-12-14

Publications

Metelerkamp Cappenberg T, De Schepper S, Vangestel C, De Lombaerde S, Wyffels L, Van den Wyngaert T, Mattis J, Gray B, Pak K, Stroobants S, Elvas F. First-in-human study of a novel cell death tracer [99mTc]Tc-Duramycin: safety, biodistribution and radiation dosimetry in healthy volunteers. EJNMMI Radiopharm Chem. 2023 Aug 30;8(1):20. doi: 10.1186/s41181-023-00207-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[99mTc]Tc-Duramycin	Peptide	6 mbq/kg	Intravenous

Indications

No indication recorded.